Tom Hutson, DO, PharmD, reviews the case of a 59-year-old woman with metastatic renal cell carcinoma, with intermediate risk and the role of risk assessment in patient management.
Case Analyses in Renal Cell Carcinoma
The expert panel discusses systemic therapy options recommended in NCCN Guidelines for patient with intermediate- and poor-risk mRCC.
Renal cell carcinoma experts discuss key efficacy data for first-line immunotherapy combinations in intermediate- and poor-risk patients with mRCC.
Tom Hutson, DO, PharmD, reviews data from phase 3 CLEAR trial that evaluates efficacy and safety of frontline lenvatinib and pembrolizumab or everolimus or sunitinib.
The expert panel discusses practical considerations when choosing first-line treatment in mRCC in light of CLEAR trial data.
Tom Hutson, DO, PharmD, discusses efficacy and data from CheckMate 9ER, a phase 3 study, and considerations in selecting this regimen.
Renal cell carcinoma panel discusses factors impacting first-line treatment selection and patient monitoring and adverse-event management in patients with intermediate- and poor-risk mRCC.
Eric Jonasch, MD, discusses a 62-year-old man with favorable-risk metastatic RCC and goals and treatment options for such a patient.
The expert panel and Dr Eric Jonasch discuss data on first-line immunochemotherapy combinations for favorable-risk mRCC.
Eric Jonasch, MD, and the panel discuss NCCN Guidelines’ preferred second-line treatment options in mRCC.
RCC experts discuss dose modifications and management of adverse events in patients with favorable-risk mRCC.
Dr Eric Jonasch and the panel discuss TIVO-3 trial data and use of tivozanib and HIF3α inhibitors in mRCC.
Bradley McGregor, MD, reviews the case of a 62-year-old man with mRCC and the use of adjuvant therapy for RCC.
The expert panel discusses the role of multidisciplinary teams in treatment of patients with RCC.
Bradley McGregor, MD, reviews data from the Keynote-564 study on the use of immunotherapy in the adjuvant setting.
The expert panel discusses trials underway in the adjuvant setting and the role of adjuvant therapy in patients with RCC.